Patrik Andersson

Senior Scientist in cancer therapeutics, San Diego | Former postdoc at MGH & HMS, Boston | PhD from Karolinska Institute, Sweden

[Patrik Andersson @pcandersson]

CAR-T cell therapy can be great, but.. the T cells express PD1 and get exhausted. Check out this #GIF I made for a recent @jitcancer paper on this topic (https://t.co/NjHbsUbron)
___
#cancer #immunotherapy #AcademicChatter #AcademicTwitter #scicomm (credit: @Biorender)

[Patrik Andersson @pcandersson]

Just like people, T cells get exhausted. Taking a break helps!

Here, the authors developed a SNIP CAR - “a protease-based platform for regulating CAR activity using an FDA-approved small molecule”, which showed diminished T cell exhaustion https://t.co/fQ26CGLQZ9

#Immunotherapy

[Patrik Andersson @pcandersson]

How can regulatory T cells (Tregs) be depleted in cancer?

In this recent paper in @ScienceTM, the authors show how dual targeting of CTLA4 and CD47 on Tregs is effective. https://t.co/1CD2bOfpdi

#AcademicTwitter #Immunotherapy @UTSWNews

[Patrik Andersson @pcandersson]

What’s happening with CAR-T cells and beyond in cancer?

This nice review summarizes recent advances and efforts to leverage T cells and NK cells. https://t.co/eTLJDclkMr

#Immunotherapy #AcademicTwitter

[Patrik Andersson @pcandersson]

Can pre-treatment with targeted therapy influence response to subsequent immunotherapy?

Here, they show that "when tumors relapse after anti-MAPK targeted therapy, they are cross-resistant to immunotherapies". https://t.co/n2nFdq2xiZ

#Immunotherapy @NatureCancer

[Patrik Andersson @pcandersson]

Can immunotherapy provide long-term responses?

Median survival (months) for metastatic melanoma was reported at ASCO for:
CTLA4 + PD1 👉 72.1
PD1 👉 36.9
CTLA4 👉 19.9

#AcademicTwitter #cancer #Immunotherapy @ASCOPost
https://t.co/t2HOJWev1T

[Patrik Andersson @pcandersson]

Predicting response to immunotherapy is important, but what’s a good marker?

Here they show how TCR clonality of tumor-infiltrating T cells predict anti-PD1 efficacy: https://t.co/DY4zOXAb3f

#AcademicTwitter #cancer #immunotherapy @NatureComms

[Patrik Andersson @pcandersson]

Does tumor location/tissue site matter?

Here they show how the same tumor cell line display different take rates, immune infiltration, and response to immunotherapy depending on where the tumor grows. https://t.co/5NsejiTv6V

#AcademicTwitter #cancer #Immunotherapy @CIR_AACR

[Patrik Andersson @pcandersson]

How do tumor cells survive in the circulation?

This recent paper highlights the importance of CCL5 as a mediator of immune evasion. https://t.co/f4mnpGD6dw

#AcademicTwitter #cancer @NatureComms

[Patrik Andersson @pcandersson]

@Tcellogic @patrickreville Such clever and beautiful illustration👏🏻

[Patrik Andersson @pcandersson]

@patrickreville @NatImmunol @ljiresearch I agree! The conclusion is more based on the clinical data, which is intriguing

[Patrik Andersson @pcandersson]

When to give immunotherapy?

Giving anti-CTLA4 BEFORE anti-PD1 was found to be superior in this recent paper: https://t.co/jNWrMwIF8s

#AcademicTwitter #Immunotherapy @NatImmunol @ljiresearch

[Patrik Andersson @pcandersson]

#cancer #Immunotherapy

[Patrik Andersson @pcandersson]

Who will respond to immunotherapy?

This recent paper suggests that the tumor microenvironment falls into 4 categories and can predict therapeutic response: https://t.co/bQnkt6t0zn #AcademicTwitter @MDAndersonNews @BostonGeneCorp

[Patrik Andersson @pcandersson]

Cool new finding and beautiful images when researchers identify "a link between sensory neurons activation and the immune system". #AcademicTwitter #phdchat

https://t.co/w3URD2RKG3

[Natalia de Menezes Lopes, PhD @nataliamlopes_]

Send a picture of something that shows very clearly you are a Grad/Undergrad student! This is mine 🤣

#phdchat @AcademicChatter @OpenAcademics @PhDVoice

[Patrik Andersson @pcandersson]

Repurposing of drugs for cancer is already a popular strategy. Should all drugs, within reason, that have passed toxicity studies in any indication, be tested in preclinical models of cancer in a high-throughput manner? #AcademicTwitter

[Patrik Andersson @pcandersson]

Just me having too much fun editing this video! Tell me more about you #phdchat #phdlife #postdoc #academictwitter

[OpenAcademics @OpenAcademics]

Let me know if you have entered this graphical abstract contest at @BioRender - I would love to share yours❤️
#AcademicTwitter #phdchat #scicomm https://t.co/Op7oJLZUzG

[Patrik Andersson @pcandersson]

It really hits me hard seeing young people die in cancer. Moments of feeling hopeless is exchanged with motivation. Motivation to do better, to contribute to better therapies.

What's your motivation? #AcademicTwitter #cancer #phdchat #beatcancer

[Patrik Andersson @pcandersson]

Making friends with scorpions? 🦂

Enter this competition at @BioRender or just vote for my contribution 😃 #AcademicTwitter #sciencetwitter #phdchat #scicomm #cancer #Immunity #scicomm

Link: https://t.co/haBy9nk10e